Kestra Medical Technologies (NASDAQ:KMTS) Director Sells 3,908 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Mary Kay Ladone sold 3,908 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total transaction of $98,481.60. Following the transaction, the director directly owned 37,507 shares of the company’s stock, valued at approximately $945,176.40. This represents a 9.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 2.1%

Shares of KMTS traded down $0.50 during mid-day trading on Thursday, hitting $23.57. The company had a trading volume of 310,496 shares, compared to its average volume of 240,413. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The business’s 50-day simple moving average is $25.42 and its 200-day simple moving average is $22.71. The stock has a market cap of $1.38 billion, a PE ratio of -9.74 and a beta of 0.62. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Sell-side analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on KMTS shares. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Oppenheimer started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. Finally, BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.14.

Institutional Trading of Kestra Medical Technologies

Institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the last quarter. Rhumbline Advisers raised its position in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after acquiring an additional 874 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after acquiring an additional 1,392 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.